VJHemOnc Podcast
VJHemOnc
The Video Journal of Hematological Oncology (VJHemOnc) podcast covers the latest hematological oncology and hematology news from international experts – from leukemias, lymphomas, MDS and MPNs, to sickle cell, aplastic anemia and rare diseases. Made for healthcare professionals and researchers, we are a global, independent, open-access platform. Listen to the latest news, including cutting-edge trial updates, controversies and opinion. If you enjoy the podcast, please leave us a rating and review! For more news visit www.vjhemonc.com
Episodes
Mentioned books
Apr 19, 2021 • 44min
The Myeloma Sessions: Post-ASH 2020 UK Discussion
Experts discuss the latest research in myeloma presented at ASH 2020, including combination therapies, BCMA-targeted treatment modalities, and novel therapies like CAR-T and BiTEs. They also compare transplant strategies and induction approaches, explore different treatment regimens and combination therapies, and highlight the challenges in treating myeloma in older populations.
Apr 15, 2021 • 18min
The Post-EBMT for Trainees VJSessions
Trainees in the field of bone marrow transplant and cellular therapy discuss the goals of the EBMT Trainee Committee and the importance of trainee inclusion. They share insights on building a trainee community, organizing informative sessions, and providing practical guidance. The podcast also highlights struggles faced by trainees and solutions provided by speakers. The success of the first session in the EBMT educational program is mentioned, along with an invitation for new members to join and the upcoming EVMT 2022 event.
Apr 13, 2021 • 33min
Post-ASH Amyloidosis Session from VJHemOnc
Experts discuss highlights from ASH 2020 including the ANDROMEDA study on AL amyloidosis treatment, use of monoclonal antibodies, high mortality in cardiac patients, challenges in diagnosing and treating amyloidosis, and the potential benefits and challenges of daratumumab.
Apr 7, 2021 • 35min
The Post-EBMT VJSessions from VJHemOnc
Guest Christian Chabannon, MD, PhD, chairs a discussion on the takeaways from the EBMT 2021 meeting, including updates in conditioning, managing graft-versus-host disease, transplantation in rarer hematological malignancies, and immune effector cell therapies.
Apr 6, 2021 • 14min
Post-EBMT highlights in acute myeloid leukemia
Phase 3 trial shows the impact of omeudubusul on patient outcomes. Omeudubusul reduces infections and increases hospital-free days. TKI maintenance therapy benefits FLIP-3 ITD positive AML patients. Comparison study reveals no difference in non-relapse mortality but increased GVHD incidence in TKI maintenance group. Promising antibody therapies including CD33-directed antibodies and T-cell redirection strategies for AML treatment.
Mar 17, 2021 • 30min
The CLL Sessions: highlights from ASH 2020
Leading experts in the CLL field discuss key data presented at ASH 2020, including fixed duration venetoclax-based regimens and LOXO305. They also explore the dynamics of minimal residual disease in CLL patients and discuss the potential of non-covalent BTK inhibitors. The importance of MRD studies and CAR-T cell therapy for salvaging patients is also highlighted.
Mar 17, 2021 • 35min
The Lymphoma Sessions: highlights from ASH 2020
Leading experts discuss highlights from ASH 2020, including bi-specific antibody therapies, management of CNS involvement, Vipa regimen benefits and cost comparison with CAR-T therapy, transplantation options and outcomes, and drug combinations, response rates, and precision medicine in lymphoma treatment.
Mar 17, 2021 • 1h 10min
The MDS Sessions: Giants in MDS
Pioneers in MDS research discuss its evolution, classification system, prognostic scoring, and treatment advancements. They highlight the importance of collaboration and technological advancements in MDS research.
Mar 16, 2021 • 13min
Latest therapies in AML: IMGN632, magrolimab & gilteritinib
The podcast discusses the latest therapies in acute myeloid leukemia (AML) presented at the virtual ASH 2020 meeting. Topics include the potential of an investigational antibody drug conjugate in combination with venetoclax and azacitidine, the use of magrolimab plus azacitidine in AML patients with P53 mutation, the synergistic effect of venetoclax and gilteritinib in flip three mutated AML, and a study comparing the efficacy and safety of combination therapy with single agent treatment for AML.
Feb 23, 2021 • 51min
VJSession: EBMT/EHA CAR-T Nursing Session
Leading nurses in hematological oncology discuss the role of palliative care in CAR T therapy. They also cover new products, survivorship, and the importance of integrating palliative care. The chapter explores establishing a multi-disciplinary communication board and the potential of CAR T therapy in solid tumors. Support for patients and future advancements are also discussed. The speakers emphasize the future of CAR T cell therapies and the role of nurses including outpatient delivery, patient selection, and education.
